This webinar discusses an approach that uses machine learning and epigenetic signatures to more effectively diagnose brain tumors.
New applications are emerging that use data-driven DNA methylation classifiers to vastly improve the accuracy of solid tumor classifications, especially for brain tumors and sarcoma.
DNA methylation technology is becoming part of a new precision medicine paradigm for central nervous system tumor diagnostics that uses epigenetics as a more accurate tool than standard pathology to guide diagnostic decisions at the time of initial presentation.
In this webinar, Matija Snuderl of NYU Langone Medical Center shares details of his team's work developing and implementing DNA methylation-based classification of brain tumors in the clinical setting.
Matija Snuderl, MD
Associate Professor, Department of Pathology
Director Molecular Pathology
NYU Langone Health